Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure (GALACTIC)

H

Heidelberg University

Status

Completed

Conditions

Coronary Artery Disease
Heart Failure
Cardiomyopathies

Study type

Observational

Funder types

Other

Identifiers

NCT01210157
GL_LGALS3BP

Details and patient eligibility

About

The purpose of this study is to determine whether galectin-3 binding protein plasma levels can predict adverse cardiovascular events in patients with coronary artery disease and/or heart failure.

Full description

Chronic heart failure represents an important cause of disease burden in Western countries. Heart failure can be either caused by vascular disease (i.e. cardiomypathy (CMP) due to coronary artery disease ("ischemic/ICMP")) or by myocardial conditions (i.e. dilated cardiomyopathies (DCMP) resulting from other causes like familial disposition, drug toxicity, etc.). Gold standard for the diagnosis of CMPs is the coronary angiography in conjunction with left ventricular angiography and myocardial biopsy, non-invasive markers include C-reactive protein (CRP) for ICMP and brain natriuretic protein (BNP) for DCMP. We have previously identified G3BP to be overexpressed in foam cells and plasma-derived microparticles, both potentially important in formation of atherosclerotic plaque. Galectin-3 binding protein (G3BP) is a secreted protein that is involved in cell adhesion and immune activation. The purpose of the current study is to test, whether G3BP plasma levels (a) are able to non-invasively differentiate causes of CMP and (b) are a suitable means for future risk assessment in CMP patients.

Enrollment

373 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

impaired ventricular function

Exclusion criteria

  • neoplastic disease
  • infections with hepatitis C or HIV

Trial design

373 participants in 2 patient groups

I Ischemic CMP
Description:
Patients with impaired ventricular function caused by coronary artery disease.
II CMP
Description:
Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems